Transdermal Hormone Therapy Better than Oral
Michael P. Goodman, MD, medical director of the Menopausal Clinic of the Caring for Women Wellness Center in Davis, Calif has told Endocrine Today that
“the risk attributed to estrogens, especially venous thromboembolism, stroke and testosterone levels are all the result of oral products and not the low-dose transdermal HT product” and that
“Clinicians should not be afraid to prescribe estrogens, especially in women near menopause, in the pre-perimenopause state and in the immediate postmenopausal state. Estrogens have received a bad name because certain studies included only oral HT products.”
